Sylvester Comprehensive Cancer Center

  • AEWS1221 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    		Coordinator:
    RCemailImg Nuria Garantiva
    RCphone 3052437130

    IRB: 20170458

    		SDG: Pediatric Cancer
    Disease Site(s):

    Bones and Joints
    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester
    Title:

    AEWS1221: Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
    Eligibility Criteria - NCT02306161 *This information has been extracted from " www.clinicaltrials.gov"

  • ADVL1622 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    		Coordinator:
    RCemailImg Wendy Best
    RCphone 3052430844

    IRB: 20170579

    		SDG: Pediatric Cancer
    Disease Site(s):

    Kidney,Bones and Joints
    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester
    Title:

    ADVL1622: Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with refractory Sarcomas, Wilms Tumor, and Other Rare Tumors.
    Eligibility Criteria - NCT02867592 *This information has been extracted from " www.clinicaltrials.gov"

  • 20170991 - Huang Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    		Coordinator:
    RCemailImg Juan Salvador

    IRB: 20170991

    		SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Corpus Uteri
    Sponsor: SCCC

    Enrolling Sites:

    Sylvester
    Title:

    A Phase I, Open-label, Dose-Escalation, Study of Trabectedin [T] in Combination with Fixed Doses of Doxorubicin [D] and Olaratumab [O] in Patients with Metastatic or Recurrent Leiomyosarcoma
    Eligibility Criteria - NCT03437070 *This information has been extracted from " www.clinicaltrials.gov"

  • VYR-VSV2-101 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    		Coordinator:
    RCemailImg Tamara Leon Aliz
    RCphone 3052430865

    IRB: 20170023

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Lung,Melanoma, skin,Kaposis sarcoma
    Sponsor: VYRIAD

    Enrolling Sites:

    Sylvester
    Title:

    Phase I Trial of Intratumoral Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and human interferon beta (VSV-IFNß-NIS), in Patients with Refractory Solid Tumors
    Eligibility Criteria - NCT02923466 *This information has been extracted from " www.clinicaltrials.gov"

  • AMC-085 - Ramos, Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    		Coordinator:
    RCemailImg Dilanis Perche

    IRB: 20130992

    		SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Hodgkin Lymphoma
    Sponsor: AMC

    Enrolling Sites:

    Sylvester
    Title:

    A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the treatment of stage II-IV HIV-associated Hodgkin Lymphoma
    Eligibility Criteria - NCT01771107 *This information has been extracted from " www.clinicaltrials.gov"

  • Anlotinib AL3818-US-004A - Trent, Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    		Coordinator:
    RCemailImg Lizbeth Bornote
    RCphone 3052436817

    IRB: 20170072

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Soft Tissue
    Sponsor: ADVENCHEN LABORATORIES

    Enrolling Sites:

    Sylvester
    Title:

    AL3818-US-004A: Phase III Study of AL3818 (Anlotinib) Hydrochloride Monotherapy in Subjects with Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
    Eligibility Criteria - NCT03016819 *This information has been extracted from " www.clinicaltrials.gov"

  • 20150932 - Trucco Matteo

  • Investigator:
    Matteo Trucco
    RCname Email

    		Coordinator:
    RCemailImg Lizbeth Bornote
    RCphone 3052436817

    IRB: 20150932

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Soft Tissue
    Sponsor: SCCC

    Enrolling Sites:

    Sylvester
    Title:

    A Phase II Trial of Concurrent Axitinib and Pembrolizumab in Subjects with Advanced Alveolar Soft Part Sarcoma (ASPS) and Other Soft Tissue Sarcomas (STS)
    Eligibility Criteria - NCT02636725 *This information has been extracted from " www.clinicaltrials.gov"

  • 20160793 - Trucco Matteo

  • Investigator:
    Matteo Trucco
    RCname Email

    		Coordinator:
    RCemailImg Eva Pavicic
    RCphone 3052437846

    IRB: 20160793

    		SDG: Pediatric Cancer
    Disease Site(s):

    Kaposis sarcoma
    Sponsor: Moffitt Cancer Center

    Enrolling Sites:

    JMH
    Sylvester
    Title:

    Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
    Eligibility Criteria - NCT02945800 *This information has been extracted from " www.clinicaltrials.gov"

  • Dendritic Cell Vaccine - Trucco, Matteo

  • Investigator:
    Matteo Trucco
    RCname Email

    		Coordinator:
    RCemailImg Lizbeth Bornote
    RCphone 3052436817

    IRB: 20110462

    		SDG: Pediatric Cancer
    Disease Site(s):

    Bones and Joints
    Sponsor: SCCC

    Enrolling Sites:

    JMH
    Sylvester
    Title:

    A Phase I Trial of Dendritic Cell Vaccination For Children And Adults With Sarcoma.
    Eligibility Criteria - NCT01803152 *This information has been extracted from " www.clinicaltrials.gov"